ISSUE 1459
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Olodaterol (Striverdi Respimat – Boehringer Ingelheim), a new inhaled long-acting beta2-agonist, has been approved by the FDA for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). It is not approved for treatment of acute exacerbations of COPD or for treatment of asthma. Olodaterol is the third long-acting beta2-agonist to be approved by the FDA for once-daily use; indacaterol (Arcapta Neohaler),1 which is available as a single agent, and vilanterol, which is available only in fixed-dose combinations with the long-acting anticholinergic umeclidinium (Anoro Ellipta) or the corticosteroid fluticasone furoate (Breo Ellipta), were approved earlier.2,3
MAINTENANCE TREATMENT — In patients with moderate to severe
... more- Indacaterol (Arcapta Neohaler) for COPD. Med Lett Drugs Ther 2012; 54:33.
- Anoro Ellipta: an inhaled umeclidinium/vilanterol combination for COPD. Med Lett Drugs Ther 2014; 56:30.
- Breo Ellipta: an inhaled fluticasone/vilanterol combination for COPD. Med Lett Drugs Ther 2013; 55:69.
- Drugs for asthma and COPD. Treat Guidel Med Lett 2013; 11:75.
- GJ Feldman et al. The 24-h FEV1 time profile of olodaterol once daily via Respimat and formoterol twice daily via Aerolizer in patients with GOLD 2-4 COPD: results from two 6-week crossover studies. Springerplus 2014; 3:419.
- GT Ferguson et al. Efficacy and safety of olodaterol once daily delivered via Respimat in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis 2014; 9:629.
- A Koch et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis 2014; 9:697.
- NS Roskell et al. Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. Int J Chron Obstruct Pulmon Dis 2014; 9:813.
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1459b
Electronic, downloadable article - $45
